Canonical: https://ownershiptrace.com/13f/companies/651

# Who owns Theravance Biopharma, Inc. (TBPH)? Elite investor 13F holders

4 tracked elite investors reported holding Theravance Biopharma, Inc as of 2026-06-30, including Irenic Capital, D.E. Shaw, Oasis Management, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

4 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic…

## Reported holders and securities, including exits (up to 20)

| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|  --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| [Irenic Capital](https://ownershiptrace.com/13f/investors/99) | THERAVANCE BIOPHARMA INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 46936116.00 USD | 2760948.000000 | Shares | hold | [Original filing](https://www.sec.gov/Archives/edgar/data/1929389/0001929389-26-000007-index.html) |
| [D.E. Shaw](https://ownershiptrace.com/13f/investors/98) | THERAVANCE BIOPHARMA INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 20151630.00 USD | 1185390.000000 | Shares | add | [Original filing](https://www.sec.gov/Archives/edgar/data/1009207/0001104659-26-097217-index.html) |
| [Oasis Management](https://ownershiptrace.com/13f/investors/141) | THERAVANCE BIOPHARMA INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 9919330.00 USD | 583490.000000 | Shares | hold | [Original filing](https://www.sec.gov/Archives/edgar/data/1317904/0001317904-26-000005-index.html) |
| [Renaissance Technologies LLC](https://ownershiptrace.com/13f/investors/63) | THERAVANCE BIOPHARMA INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 2623406.00 USD | 154318.000000 | Shares | add | [Original filing](https://www.sec.gov/Archives/edgar/data/1037389/0001037389-26-000059-index.html) |
| [Tudor Investment](https://ownershiptrace.com/13f/investors/94675) | THERAVANCE BIOPHARMA INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | [Original filing](https://www.sec.gov/Archives/edgar/data/923093/0000902664-26-003485-index.html) |
| [Gotham Asset Management](https://ownershiptrace.com/13f/investors/94672) | THERAVANCE BIOPHARMA INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | [Original filing](https://www.sec.gov/Archives/edgar/data/1510387/0001398344-26-014644-index.html) |

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

[How to read the data](https://ownershiptrace.com/docs#reading-the-data) · [Disclaimer](https://ownershiptrace.com/disclaimer)